Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 4, 2015
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical OncologyA Goday, I Barneto, J M García-Almeida, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 12, 2017
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical OncologyP Pérez-Segura, J E Palacio, L Vázquez, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2015
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive TumoursJ Sastre, B Massuti, G Pulido, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialA Abad, E Martínez-Balibrea, J M Viéitez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancerM J Sotelo, J Sastre, M L Maestro, et al.
ESMO Open|November 28, 2024
Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trialP García-Alfonso, E Elez, J Soto-Alsar, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 27, 2023
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patientsM Toledano-Fonseca, M A Gómez-España, E Élez, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Safety and efficacy of encorafenib-cetuximab combination in BRAF V600E -mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter studyA Fernández-Montes, J Ros, P García-Alfonso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2018
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD studyE Aranda, P García-Alfonso, M Benavides, et al.
Pageof 3